Vancomycin: an update (Q39746652)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Vancomycin: an update	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

Europe PubMed Central

Vancomycin: an update (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

author name string

Cheung RP

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

DiPiro JT

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

1 July 1986

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

153-169

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Vancomycin Revisited

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

The structure and mode of action of glycopeptide antibiotics of the vancomycin group

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Specificity of combination between mucopeptide precursors and vancomycin or ristocetin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

A new type of penicillin resistance of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Interaction Between Vancomycin and Rifampin Against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Bacteremia caused by a previously unidentified species of rapidly growing Mycobacterium successfully treated with vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

L FORMS OF STAPHYLOCOCCUS AUREUS.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Hazards of Rapid Administration of Vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin toxicity: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin Ototoxicity in a Patient with Normal Renal Function

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin ototoxicity in patients with normal renal function

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Thrombocytopenia due to vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin and cardiac arrest

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Cardiac arrest following administration of vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Desensitization to vancomycin.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Safety of oral vancomycin in functionally anephric patients

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Oral vancomycin for antibiotic-associated pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Clinical pharmacology and efficacy of vancomycin in pediatric patients.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin concentration in human tissues —preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Effects of hepatic function on vancomycin clinical pharmacology

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Effect of meningitis and probenecid on the penetration of vancomycin into cerebrospinal fluid in rabbits

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin for Staphylococcal Shunt Site Infections in Patients on Regular Haemodialysis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

The nephrotoxicity of antimicrobial agents (second of three parts).

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Pharmacokinetics of vancomycin in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin pharmacokinetics in normal and morbidly obese subjects

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

A simplified dosing method for initiating vancomycin therapy.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Pharmacokinetics of vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Kinetic model for gentamicin dosing with the use of individual patient parameters

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Treatment of Clostridium difficile colitis and diarrhea with vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Vancomycin therapy of severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Combination antibiotic therapy of bacterial endocarditis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Oral antibiotic prophylaxis in protected environment units: effect of nonabsorbable and absorbable antibiotics on the fecal flora

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Role of Vancomycin as a Component of Oral Nonabsorbable Antibiotics for Microbial Suppression in Leukemic Patients

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Behaviour in vitro of some new antistaphylococcal antibiotics.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antibiotic-tolerant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N -Formimidoyl Thienamycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Methicillin-resistant Staphylococcus aureus. Antimicrobial susceptibility.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

An Outbreak of Infections Caused by Strains of Staphylococcus aureus Resistant to Methicillin and Aminoglycosides. I. Clinical Studies

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

A large outbreak of infections caused by a strain of Staphylococcus aureus resistant of oxacillin and aminoglycosides.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Bacteremia due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Effect of inoculum size on in vitro susceptibility of methicillin-resistant Staphylococcus aureus to eighteen antimicrobial agents

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility and Synergy Studies of Methicillin-Resistant Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Synergy of Vancomycin plus Cefazolin or Cephalothin against Methicillin-Resistant Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Comparison of antimicrobial susceptibility patterns among coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antimicrobial susceptibilities of coagulase-negative staphylococci isolated from urinary infections

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility of Pneumococci and Haemophilus influenzae to Antibacterial Agents

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Emergence of Multiply Resistant Pneumococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility of Beta-Hemolytic Streptococci to 65 Antibacterial Agents

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Synergism with Aminoglycosides of Penicillin, Ampicillin and Vancomycin Against Non-Enterococcal Group-D Streptococci and Viridans Streptococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Serious infections caused by diphtheroids

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Sepsis with a new species of Corynebacterium

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Susceptibility of human skin aerobic diphtheroids to antimicrobial agents in vitro

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Clinical and laboratory aspects of Listeria monocytogenes infections. With a report of ten cases

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antibiotic susceptibility and synergy of clinical isolates of Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Antimicrobial susceptibilities of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Standardized antimicrobial disc susceptibility testing of anaerobic bacteria: in vitro susceptibility of Clostridium perfringens to nine antibiotics

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Mode of action and in-vitro activity of vancomycin

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1986.TB03471.X

21 January 2018

Identifiers

10.1002/J.1875-9114.1986.TB03471.X

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39746652&oldid=2089281418"